Skip to main content
Article
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
The Lancet Diabetes & Endocrinology (2018)
  • Katherine R Tuttle, University of Washington
  • Mark C Lakshmanan, Eli Lilly and Company
  • Brian Rayner, University of Cape Town
  • Robert S Busch, Albany Medical College
  • Alan G Zimmermann, Eli Lilly and Company
  • D Bradley Woodward, Eli Lilly and Company
  • Fady T Botros, Eli Lilly and Company
Publication Date
August 1, 2018
DOI
10.1016/S2213-8587(18)30104-9
Citation Information
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Robert S Busch, et al.. "Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial" The Lancet Diabetes & Endocrinology Vol. 6 Iss. 8 (2018) p. 605 - 617
Available at: http://works.bepress.com/katherine-tuttle/175/